Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ch14.18/CHO plus subcutaneous IL-2 after haploidentical stem cell transplantation for relapsed neuroblastoma
2009-015936-14Phase 2Completed
- Sponsor
- University Children's Hospital Tübingen
- Start
- Feb 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Dinutuximab beta and aldesleukin in neuroblastoma, sponsored by University Children's Hospital Tübingen. Primary endpoint: Success of treatment. Started Feb 2010; status: completed.
02
Drugs
Dinutuximab betaaldesleukin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2009-015936-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015936-14.